Hagens Berman probes Erasca investor claims over ERAS-0015 disclosures

The firm says it is investigating a proposed shareholder class action tied to Erasca’s disclosures about its lead oncology candidate, ERAS-0015, ahead of an Aug. 10 lead-plaintiff deadline.

Hagens Berman said in an Aug. 6, 2026, investor alert that it is investigating claims in a proposed class action against Erasca, Inc. over alleged securities-law violations tied to disclosures about ERAS-0015. Erasca trades on Nasdaq under the ticker ERAS.

The notice says the case centers on claims that Erasca and senior executives misled investors about ERAS-0015’s competitive advantage, safety profile and intellectual property moat. It says the drug was repeatedly described during the class period as a “best-in-class” pan-RAS molecular glue.

The release says the class period runs from Jan. 14, 2025, through Apr. 26, 2026. It also says disclosures on Apr. 27-28, 2026, removed the alleged artificial inflation from the stock price and triggered a sharp decline that wiped out more than $2.8 billion in market capitalization.

The release says investors who bought or acquired Erasca common stock during the class period may be eligible to seek appointment as lead plaintiff in any case that moves ahead. The deadline to move for that role is Aug. 10, 2026.

The notice names Reed Kathrein, a Hagens Berman partner, as the lead investigator. In a quoted statement, Kathrein said the firm is investigating whether Erasca may have intentionally misled investors about ERAS-0015’s safety profile and about a potential moat in a highly competitive cancer treatment space.

The release does not include a complaint, court filing or independent reporting. It says the information comes from Hagens Berman’s investor alert and describes the firm as a national shareholder rights firm.

It also says people with non-public information about Erasca should consider options under the SEC Whistleblower program, which the notice says may provide rewards of up to 30% of any successful SEC recovery.

The next development is the Aug. 10 deadline. Investors who believe they were affected during the stated class period would need to act before then if they want to seek lead-plaintiff status, according to the release.

Sources

• PR Newswire investor alert: Erasca, Inc. investors with substantial losses have opportunity to lead shareholder class action lawsuit

Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.